<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We analyzed the outcomes of 283 patients receiving unrelated donor allogeneic hematopoietic cell transplantation for non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NHL) facilitated by the Center for International Blood and Marrow Transplant Research/National Marrow Donor Program (CIBMTR/NMDP) between 1991 and 2004 </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients received myeloablative conditioning regimens </plain></SENT>
<SENT sid="2" pm="."><plain>The median follow-up of survivors is 5 years </plain></SENT>
<SENT sid="3" pm="."><plain>Seventy-three (26%) patients are alive </plain></SENT>
<SENT sid="4" pm="."><plain>The day 100 probability of <z:hpo ids='HP_0011420'>death</z:hpo> from <z:hpo ids='HP_0000001'>all</z:hpo> causes is estimated at 39% </plain></SENT>
<SENT sid="5" pm="."><plain>The cumulative incidence of developing grade III-IV <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> (aGVHD) at day 100 is 25% </plain></SENT>
<SENT sid="6" pm="."><plain>The estimated 5-year survival and failure free survival are 24% (95% confidence interval [CI]: 19-30) and 22% (95% CI: 17-28), respectively </plain></SENT>
<SENT sid="7" pm="."><plain>Factors adversely associated with overall survival (OS) included increasing age, decreased performance status, and refractory disease </plain></SENT>
<SENT sid="8" pm="."><plain>Follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (FL) and peripheral T cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> had improved survival compared to aggressive B cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>Factors adversely associated with progression-free survival (PFS) included performance status, histology, and disease status at transplant </plain></SENT>
<SENT sid="10" pm="."><plain>Long-term failure-free survival is possible following unrelated donor transplantation for NHL, although early mortality was high in this large cohort </plain></SENT>
</text></document>